Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Type-2-Diabetes-Mellitus"

37 News Found

Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes
News | March 24, 2025

Lilly launches Mounjaro in India for treatment of obesity and type 2 diabetes

Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)


Morepen launches Empamore for diabetes care with affordable treatment
News | March 18, 2025

Morepen launches Empamore for diabetes care with affordable treatment

Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health


Akums combines two potent diabetes medicines for enhanced treatment efficacy
News | February 04, 2025

Akums combines two potent diabetes medicines for enhanced treatment efficacy

Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management


Zydus inks agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary
News | January 07, 2025

Zydus inks agreement with CVS Caremark to add Zituvio, Zituvimet and Zituvimet XR to its template formulary

These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route


Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio
News | December 31, 2024

Lupin acquires Huminsulin from Lilly to enhance diabetes portfolio

The huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and childre


Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
News | December 14, 2024

Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio

The trademark rights for these brands will be transferred to Lupin by March next year.


Lupin gets tentative approval from USFDA for Sitagliptin and Metformin Hydrochloride Tablets
Drug Approval | December 05, 2024

Lupin gets tentative approval from USFDA for Sitagliptin and Metformin Hydrochloride Tablets

Sitagliptin and Metformin Hydrochloride Tablets, 50 mg/500 mg and 50 mg/1000 mg are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus


Torrent Pharma inks agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands
News | December 05, 2024

Torrent Pharma inks agreement with Boehringer Ingelheim to acquire 3 anti-diabetes brands

The acquisition further strengthens Torrent’s existing diabetes care portfolio and its presence in the Oral Anti Diabetic market


India emerging as world-class cost-effective healthcare destination and global pharma leader: Dr. Jitendra Singh
Policy | August 07, 2024

India emerging as world-class cost-effective healthcare destination and global pharma leader: Dr. Jitendra Singh

He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries


Briefs: Zydus Lifesciences and Divi's Laboratories
Drug Approval | July 22, 2024

Briefs: Zydus Lifesciences and Divi's Laboratories

Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets